Cycle Pharmaceuticals · 1 day ago
Rare Disease Account Manager - Oncology - Baltimore
Cycle Pharmaceuticals is a company dedicated to supporting patients with rare diseases, particularly in the hematology and oncology sectors. They are seeking a Rare Disease Account Manager to engage healthcare professionals, educate on treatment pathways, and drive the adoption of their therapies while collaborating cross-functionally to ensure successful product launches.
Pharmaceutical
Responsibilities
Drive adoption of Cycle Pharmaceuticals leading rare disease therapies across hematology and oncology by engaging with physicians, nurses, and healthcare staff through face-to-face and virtual channels
Build awareness of rare disease conditions, therapeutic solutions, and the individualized support services available through Cycle Vita
Educate providers on prescribing pathways and work closely with our HUB team to streamline patient access to treatments
Identify, engage, and partner with key opinion leaders to support peer-to-peer education and community outreach
Lead territory-level execution of new product launches and marketing strategies to maximize reach and impact
Collaborate cross-functionally with Medical Affairs, Marketing, and Field Leadership to align on strategy and field insights
Ensure accurate CRM documentation, maintain compliance, and develop and deliver quarterly business plans tailored to your market dynamics
Qualification
Required
Bachelor's degree required
Proven successful field-based sales experience in biopharmaceuticals
Proven ability to meet/exceed performance goals
Collaborative, ethical, and proactive team player
Strong communication and CRM/data skills
Willingness to travel up to 70%
Valid driver's license and clean driving record
Preferred
Experience in hematology, oncology, and/or rare disease markets strongly preferred
Benefits
Employer funded private health insurance
Life insurance
401(k) plan
Company
Cycle Pharmaceuticals
Cycle Pharmaceuticals is a pioneering pharmaceutical company.
Funding
Current Stage
Growth StageTotal Funding
$25MKey Investors
Deutsche Bank
2020-09-07Debt Financing· $25M
Recent News
Labiotech UG
2026-01-08
FierceBiotech
2025-12-18
Labiotech UG
2025-12-17
Company data provided by crunchbase